Equivocal (HER2 IHC 2+) breast carcinomas: gene –protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits
ConclusionNon ‐heterogeneous HER2 IHC 2+ tumours tend to be HER2‐amplified. Adding the percentage of cells with HER2>6 copies to the average HER2/CEP17 ratio may facilitate assessment of amplification status in ISH ‐equivocal cases. The proportion of cells with HER2/CEP17 ≥2.0 contributes information concerning the actual average HER2/CEP17 ratio, depending on tumour type.
Source: Histopathology - Category: Pathology Authors: Gyula Pekar,
Ionna Kasselaki,
Agnes Pekar ‐Lukacs,
Csaba Dekany,
Dan Hellberg,
Tibor Tot Tags: Original Article Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Genetics | HER2 | Pathology | Study